Predicting cerebral vasospasm after subarachnoid hemorrhage using blood biomarkers
Predictive Model for the Occurrence of Cerebral Vasospasm Complicating Subarachnoid Haemorrhage by Combined Analysis of the Kinetics of a Panel of Biomarkers.
This study is testing if certain blood markers can help predict if patients who have had a brain bleed will develop vasospasm within two weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 1 site (Bordeaux) |
| Trial ID | NCT06303349 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a predictive model for cerebral vasospasm occurring within 14 days following subarachnoid hemorrhage. It will analyze a panel of blood biomarkers collected from patients in the neurosurgical intensive care unit over a period of 10 days. The study will follow patients until discharge or for a maximum of 14 days, with the goal of enabling earlier diagnosis and potential pre-emptive treatment of vasospasm. The relationship between biomarker levels and the occurrence of vasospasm will be assessed while keeping the measurements blinded to each other.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with subarachnoid hemorrhage within four days prior to admission to neuro-resuscitation.
Not a fit: Patients with significant vasospasm upon admission or those whose short-term survival is compromised may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and treatment of cerebral vasospasm, potentially reducing morbidity and mortality in affected patients.
How similar studies have performed: Previous studies have shown promising associations between blood biomarkers and neurological outcomes, indicating potential success for this predictive approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subarachnoid hemorrhage (of aneurysmal or non-aneurysmal etiology) less than 4 days prior to admission to neuro-resuscitation, diagnosed on clinical presentation and confirmed by brain imaging. * Free, informed and written consent signed by the patient (or, failing this, his or her representative). * Patient entitled to or affiliated with social security Exclusion Criteria: * Significant vasospasm on admission to the department, diagnosed on initial imaging * Patient whose short-term survival (48 hours) appears compromised * Contraindication to perfusion CT scan * Pregnant or breast-feeding women * Patient under legal protection (persons deprived of liberty or under guardianship)
Where this trial is running
Bordeaux
- CHU de Bordeaux — Bordeaux, France (Recruiting)
Study contacts
- Principal investigator: Grégoire CANE, Dr — University Hospital, Bordeaux
- Study coordinator: Grégoire CANE, Dr
- Email: gregoire.cane@chu-bordeaux.fr
- Phone: 0557821019
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.